Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Total Androgen Blockade With or Without Pelvic Irradiation in Prostate Cancer
NCT00002633Phase 3Completed
- Sponsor
- Canadian Cancer Trials Group
- Start
- Feb 1995
- Primary completion
- Sep 2011
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bicalutamide, buserelin, flutamide, goserelin, leuprolide and 1 more in prostate cancer (PCa) (2 arms), sponsored by Canadian Cancer Trials Group. Primary endpoint: Overall survival at 10 years. Started Feb 1995; status: completed.
02
Drugs
bicalutamidebuserelinflutamidegoserelinleuprolide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00002633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002633.